Skyhawk Therapeutics and Merck KGaA strike $2 billion deal to discover novel RNA for neurological disorders

Skyhawk Therapeutics enters into an option agreement to grant Merck KGaA, Darmstadt, Germany, exclusive global rights to drug candidates pursued under the collaboration upon option exercise

AbCellera and Biogen collaborate on neurological antibody therapy

AbCellera will receive an upfront payment and is eligible to receive additional milestone payments

Healthcare firms discover ways to use VR to treat neurological diseases, says GlobalData

The global VR market to grow at a compound annual growth rate of 13% from $7 billion in 2018 to $28 billion in 2030.

Novartis, Voyager Therapeutics reach license deal for gene therapy vectors to combat neurological diseases

Agreement builds on previous Novartis success using emerging technologies to develop first-in-class gene therapies for neurological disorders

AbbVie to acquire Gilgamesh Pharmaceuticals’ bretisilocin for $1.2 billion

Samsung India introduces next-gen mobile CT imaging solutions

The new lineup includes CereTom Elite, OmniTom Elite, OmniTom Elite PCD, and BodyTom 32/64

Athena Diagnostics enhances Ataxia testing with long-read gene sequencing

Athena is also exploring the use of this technology for expanded carrier screening

Cadila Pharmaceuticals launches Vasograin Plus for treatment of migraines

Vasograin Plus represents a major advancement in the treatment of migraine

Merck KGaA bestows 2025 Future Insight Prize to Helmholtz Center’s Magdalena Gotz for breakthroughs in brain regeneration

Prof. Götz is Director of the Institute of Stem Cell Research at Helmholtz Center Munich and Chair of Physiological Genomics at Ludwig-Maximilians-Universität, Munich

Teijin Pharma receives approval for additional indication for XEOMIN in Japan